Israel’s D-Pharm has obtained fast track status from the China’s Food and Drug Administration (CFDA) for its epilepsy treatment, DP-VPA. D-Pharm is jointly developing the treatment in China with its local partner, Jiangsu NHWA. DP-VPA has completed a first Phase II clinical trial.
http://www.globes.co.il/en/article-china-fast-tracks-d-pharm-epilepsy-drug-1000944209